Pharmacological evaluation of amikacin in neonates

J. B. Howard, G. H. McCracken

Research output: Chapter in Book/Report/Conference proceedingChapter

34 Citations (Scopus)

Abstract

The in vitro bacterial susceptibilities and pharmacokinetic properties of amikacin (BB K8) were studied in newborn infants. Gram negative bacteria and Staphylococcus aureus isolated from neonates were uniformly susceptible to 10 μg or less of amikacin per ml, and five Escherichia coli strains resistant to kanamycin were inhibited and killed by 5 μg or less of amikacin per ml. Mean peak serum concentrations of 17 to 20 μg/ml were observed 30 min after 7.5 mg/kg amikacin doses, and accumulation of drug in serum was not detected after repeated doses for 5 to 7 days. Intravenous infusion of amikacin over a 20 min period resulted in extremely low peak serum levels in four of eight infants studied. Serum half life values were correlated inversely with postnatal age and renal clearances of amikacin. The volumes of drug distribution indicate that amikacin remains primarily in the extracellular fluid space of neonates. The lack of efficacy and safety data preclude the use of amikacin in neonates at this time.

Original languageEnglish (US)
Title of host publicationANTIMICROB.AGENTS CHEMOTHER.
Pages86-90
Number of pages5
Volume8
Edition1
StatePublished - 1975

Fingerprint

Amikacin
Newborn Infant
Pharmacology
Serum
Kanamycin
Extracellular Fluid
Extracellular Space
Gram-Negative Bacteria
Intravenous Infusions
Pharmaceutical Preparations
Half-Life
Staphylococcus aureus
Pharmacokinetics
Escherichia coli
Kidney
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Howard, J. B., & McCracken, G. H. (1975). Pharmacological evaluation of amikacin in neonates. In ANTIMICROB.AGENTS CHEMOTHER. (1 ed., Vol. 8, pp. 86-90)

Pharmacological evaluation of amikacin in neonates. / Howard, J. B.; McCracken, G. H.

ANTIMICROB.AGENTS CHEMOTHER.. Vol. 8 1. ed. 1975. p. 86-90.

Research output: Chapter in Book/Report/Conference proceedingChapter

Howard, JB & McCracken, GH 1975, Pharmacological evaluation of amikacin in neonates. in ANTIMICROB.AGENTS CHEMOTHER.. 1 edn, vol. 8, pp. 86-90.
Howard JB, McCracken GH. Pharmacological evaluation of amikacin in neonates. In ANTIMICROB.AGENTS CHEMOTHER.. 1 ed. Vol. 8. 1975. p. 86-90
Howard, J. B. ; McCracken, G. H. / Pharmacological evaluation of amikacin in neonates. ANTIMICROB.AGENTS CHEMOTHER.. Vol. 8 1. ed. 1975. pp. 86-90
@inbook{188092030da74b4f84fc0e1574e53f05,
title = "Pharmacological evaluation of amikacin in neonates",
abstract = "The in vitro bacterial susceptibilities and pharmacokinetic properties of amikacin (BB K8) were studied in newborn infants. Gram negative bacteria and Staphylococcus aureus isolated from neonates were uniformly susceptible to 10 μg or less of amikacin per ml, and five Escherichia coli strains resistant to kanamycin were inhibited and killed by 5 μg or less of amikacin per ml. Mean peak serum concentrations of 17 to 20 μg/ml were observed 30 min after 7.5 mg/kg amikacin doses, and accumulation of drug in serum was not detected after repeated doses for 5 to 7 days. Intravenous infusion of amikacin over a 20 min period resulted in extremely low peak serum levels in four of eight infants studied. Serum half life values were correlated inversely with postnatal age and renal clearances of amikacin. The volumes of drug distribution indicate that amikacin remains primarily in the extracellular fluid space of neonates. The lack of efficacy and safety data preclude the use of amikacin in neonates at this time.",
author = "Howard, {J. B.} and McCracken, {G. H.}",
year = "1975",
language = "English (US)",
volume = "8",
pages = "86--90",
booktitle = "ANTIMICROB.AGENTS CHEMOTHER.",
edition = "1",

}

TY - CHAP

T1 - Pharmacological evaluation of amikacin in neonates

AU - Howard, J. B.

AU - McCracken, G. H.

PY - 1975

Y1 - 1975

N2 - The in vitro bacterial susceptibilities and pharmacokinetic properties of amikacin (BB K8) were studied in newborn infants. Gram negative bacteria and Staphylococcus aureus isolated from neonates were uniformly susceptible to 10 μg or less of amikacin per ml, and five Escherichia coli strains resistant to kanamycin were inhibited and killed by 5 μg or less of amikacin per ml. Mean peak serum concentrations of 17 to 20 μg/ml were observed 30 min after 7.5 mg/kg amikacin doses, and accumulation of drug in serum was not detected after repeated doses for 5 to 7 days. Intravenous infusion of amikacin over a 20 min period resulted in extremely low peak serum levels in four of eight infants studied. Serum half life values were correlated inversely with postnatal age and renal clearances of amikacin. The volumes of drug distribution indicate that amikacin remains primarily in the extracellular fluid space of neonates. The lack of efficacy and safety data preclude the use of amikacin in neonates at this time.

AB - The in vitro bacterial susceptibilities and pharmacokinetic properties of amikacin (BB K8) were studied in newborn infants. Gram negative bacteria and Staphylococcus aureus isolated from neonates were uniformly susceptible to 10 μg or less of amikacin per ml, and five Escherichia coli strains resistant to kanamycin were inhibited and killed by 5 μg or less of amikacin per ml. Mean peak serum concentrations of 17 to 20 μg/ml were observed 30 min after 7.5 mg/kg amikacin doses, and accumulation of drug in serum was not detected after repeated doses for 5 to 7 days. Intravenous infusion of amikacin over a 20 min period resulted in extremely low peak serum levels in four of eight infants studied. Serum half life values were correlated inversely with postnatal age and renal clearances of amikacin. The volumes of drug distribution indicate that amikacin remains primarily in the extracellular fluid space of neonates. The lack of efficacy and safety data preclude the use of amikacin in neonates at this time.

UR - http://www.scopus.com/inward/record.url?scp=0016678461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016678461&partnerID=8YFLogxK

M3 - Chapter

VL - 8

SP - 86

EP - 90

BT - ANTIMICROB.AGENTS CHEMOTHER.

ER -